Myocardial infarctectomy and repair of ruptured ventricular septum during acute stage of infarction von Trinkle, J. Kent, Furman, Richard E., Orr, James A., Reeves, John T., Bryant, Lester R.

Volltext

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study von O'Brien, Susan, Prof, Jones, Jeffrey A, MD, Coutre, Steven E, Prof, Mato, Anthony R, MD, Hillmen, Peter, Prof, Tam, Constantine, MD, Österborg, Anders, Prof, Siddiqi, Tanya, MD, Thirman, Michael J, MD, Furman, Richard R, MD, Ilhan, Osman, Prof, Keating, Michael J, Prof, Call, Timothy G, MD, Brown, Jennifer R, MD, Stevens-Brogan, Michelle, MSc, Li, Yunfeng, PhD, Clow, Fong, ScD, James, Danelle F, MD, Chu, Alvina D, MD, Hallek, Michael, Prof, Stilgenbauer, Stephan, Prof

Volltext

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies von ADVANI, Ranjana H, BUGGY, Joseph J, SUKBUNTHERNG, Juthamas, IZUMI, Raquel, HAMDY, Ahmed, HEDRICK, Eric, FOWLER, Nathan H, SHARMAN, Jeff P, SMITH, Sonali M, BOYD, Thomas E, GRANT, Barbara, KOLIBABA, Kathryn S, FURMAN, Richard R, RODRIGUEZ, Sara, CHANG, Betty Y

Volltext

Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial von O'Brien, Susan, Prof, Furman, Richard R, MD, Coutre, Steven E, Prof, Sharman, Jeff P, MD, Burger, Jan A, MD, Blum, Kristie A, MD, Grant, Barbara, MD, Richards, Donald A, MD, Coleman, Morton, Prof, Wierda, William G, MD, Jones, Jeffrey A, MD, Zhao, Weiqiang, MD, Heerema, Nyla A, Prof, Johnson, Amy J, PhD, Izumi, Raquel, PhD, Hamdy, Ahmed, MD, Chang, Betty Y, PhD, Graef, Thorsten, MD, Clow, Fong, ScD, Buggy, Joseph J, PhD, James, Danelle F, MD, Byrd, John C, Prof

Volltext

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study von Byrd, John C, Furman, Richard R, Coutre, Steven E, Flinn, Ian W, Burger, Jan A, Blum, Kristie, Sharman, Jeff P, Wierda, William, Zhao, Weiqiang, Heerema, Nyla A, Luan, Ying, Liu, Emily A, Dean, James P, O'Brien, Susan

Volltext

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib von Byrd, John C., Furman, Richard R., Coutre, Steven E., Burger, Jan A., Blum, Kristie A., Coleman, Morton, Wierda, William G., Jones, Jeffrey A., Zhao, Weiqiang, Heerema, Nyla A., Johnson, Amy J., Shaw, Yun, Bilotti, Elizabeth, Zhou, Cathy, James, Danelle F., O'Brien, Susan

Volltext

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia von Brown, Jennifer R., Byrd, John C., Coutre, Steven E., Benson, Don M., Flinn, Ian W., Wagner-Johnston, Nina D., Spurgeon, Stephen E., Kahl, Brad S., Bello, Celeste, Webb, Heather K., Johnson, Dave M., Peterman, Sissy, Li, Daniel, Jahn, Thomas M., Lannutti, Brian J., Ulrich, Roger G., Yu, Albert S., Miller, Langdon L., Furman, Richard R.

Volltext

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia von Furman, Richard R, Sharman, Jeff P, Coutre, Steven E, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Stilgenbauer, Stephan, Cramer, Paula, Aiello, Maria, Johnson, Dave M, Miller, Langdon L, Li, Daniel, Jahn, Thomas M, Dansey, Roger D, Hallek, Michael, O'Brien, Susan M

Volltext

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia von Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W, Ghia, Paolo, Eradat, Herbert, Ervin, Thomas, Lamanna, Nicole, Coiffier, Bertrand, Pettitt, Andrew R, Ma, Shuo, Tausch, Eugen, Cramer, Paula, Huang, Julie, Mitra, Siddhartha, Hallek, Michael, O'Brien, Susan M, Stilgenbauer, Stephan

Volltext

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia von Byrd, John C, Furman, Richard R, Coutre, Steven E, Flinn, Ian W, Burger, Jan A, Blum, Kristie A, Grant, Barbara, Sharman, Jeff P, Coleman, Morton, Wierda, William G, Jones, Jeffrey A, Zhao, Weiqiang, Heerema, Nyla A, Johnson, Amy J, Sukbuntherng, Juthamas, Chang, Betty Y, Clow, Fong, Hedrick, Eric, Buggy, Joseph J, James, Danelle F, O'Brien, Susan

Volltext

Postibrutinib outcomes in patients with mantle cell lymphoma von Martin, Peter, Maddocks, Kami, Leonard, John P., Ruan, Jia, Goy, Andre, Wagner-Johnston, Nina, Rule, Simon, Advani, Ranjana, Iberri, David, Phillips, Tycel, Spurgeon, Stephen, Kozin, Eliana, Noto, Katherine, Chen, Zhengming, Jurczak, Wojciech, Auer, Rebecca, Chmielowska, Ewa, Stilgenbauer, Stephan, Bloehdorn, Johannes, Portell, Craig, Williams, Michael E., Dreyling, Martin, Barr, Paul M., Chen-Kiang, Selina, DiLiberto, Maurizio, Furman, Richard R., Blum, Kristie A.

Volltext

Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL von Pastore, Alessandro, Gaiti, Federico, Lu, Sydney X., Brand, Ryan M., Kulm, Scott, Chaligne, Ronan, Gu, Hongcang, Huang, Kevin Y., Stamenova, Elena K., Béguelin, Wendy, Jiang, Yanwen, Schulman, Rafael C., Kim, Kyu-Tae, Alonso, Alicia, Allan, John N., Furman, Richard R., Gnirke, Andreas, Wu, Catherine J., Melnick, Ari M., Meissner, Alexander, Bernstein, Bradley E., Abdel-Wahab, Omar, Landau, Dan A.

Volltext

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL) von Kahl, Brad S., Spurgeon, Stephen E., Furman, Richard R., Flinn, Ian W., Coutre, Steven E., Brown, Jennifer R., Benson, Don M., Byrd, John C., Peterman, Sissy, Cho, Yoonjin, Yu, Albert, Godfrey, Wayne R., Wagner-Johnston, Nina D.

Volltext

Phase Ib dose-escalation study of the selective, non-covalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies von Allan, John N, Pinilla-Ibarz, Javier, Gladstone, Douglas E, Patel, Krish, Sharman, Jeff P, Wierda, William G, Choi, Michael Y, O'Brien, Susan M, Shadman, Mazyar, Davids, Matthew S, Pagel, John M, Yimer, Habte A, Ward, Renee, Acton, Gary, Taverna, Pietro, Combs, Daniel L, Fox, Judith A, Furman, Richard R, Brown, Jennifer R

Volltext

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma von Flinn, Ian W., Kahl, Brad S., Leonard, John P., Furman, Richard R., Brown, Jennifer R., Byrd, John C., Wagner-Johnston, Nina D., Coutre, Steve E., Benson, Don M., Peterman, Sissy, Cho, Yoonjin, Webb, Heather K., Johnson, David M., Yu, Albert S., Ulrich, Roger G., Godfrey, Wayne R., Miller, Langdon L., Spurgeon, Stephen E.

Volltext

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy von Mato, Anthony R, Wierda, William G, Davids, Matthew S, Cheson, Bruce D, Coutre, Steven E, Choi, Michael, Furman, Richard R, Heffner, Leonard, Barr, Paul M, Eradat, Herbert, Ford, Sharanya M, Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A, Potluri, Jalaja, Byrd, John C

Volltext

Persistent and Relapsing Babesiosis in Immunocompromised Patients von Krause, Peter J., Gewurz, Benjamin E., Hill, David, Marty, Francisco M., Vannier, Edouard, Foppa, Ivo M., Furman, Richard R., Neuhaus, Ellen, Skowron, Gail, Gupta, Shaili, McCalla, Carlo, Pesanti, Edward L., Young, Mary, Heiman, Donald, Hsue, Gunther, Gelfand, Jeffrey A., Wormser, Gary P., Dickason, John, Bia, Frank J., Hartman, Barry, Telford, Sam R., Christianson, Diane, Dardick, Kenneth, Coleman, Morton, Girotto, Jennifer E., Spielman, Andrew

Volltext

A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia von Byrd, John C., Pagel, John M., Awan, Farrukh T., Forero, Andres, Flinn, Ian W., Deauna-Limayo, Delva P., Spurgeon, Stephen E., Andritsos, Leslie A., Gopal, Ajay K., Leonard, John P., Eisenfeld, Amy J., Bannink, Jeannette E., Stromatt, Scott C., Furman, Richard R.

Volltext

Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial von Ghia, Paolo, Coutre, Steven E, Cheson, Bruce D, Barrientos, Jacqueline C, Hillmen, Peter, Pettitt, Andrew R, Zelenetz, Andrew D, Shreay, Sanatan, Hallek, Michael, Furman, Richard R

Volltext

Clinical and Molecular Evidence of Atovaquone and Azithromycin Resistance in Relapsed Babesia microti Infection Associated With Rituximab and Chronic Lymphocytic Leukemia von Simon, Matthew S., Westblade, Lars F., Dziedziech, Alexis, Visone, Joseph E., Furman, Richard R., Jenkins, Stephen G., Schuetz, Audrey N., Kirkman, Laura A.

Volltext